BOSTON, August 1, 2016- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the appointment of four company executives to its senior-most leadership team, the Business Review Committee:

• David Godwin, Senior Vice President, Global Business Development
• Michelle Graham, Senior Vice President and Chief Human Resources Officer
• Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer
• Joshua Schultz, Senior Vice President, Worldwide Head of PAREXEL Access

“PAREXEL has a history of growth, innovation and leadership that spans more than 30 years, and these leaders have played an important role in our success,” said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL. “Our corporate strategy is to enhance our leadership in the biopharmaceutical services industry by focusing on our core business and capturing new growth from adjacent markets. We will leverage the expertise of these senior leaders to implement our strategic objectives and further transform PAREXEL, positioning the Company for future growth.”

Mr. Godwin joined PAREXEL in 1989 and is responsible for the business development efforts for many of the Company’s services. He will continue to manage global business development initiatives.

Ms. Graham joined PAREXEL in 2015 and is responsible for the design and launch of the Company’s people strategy, talent agenda and refined Human Resources operating model. She will continue to manage the company’s Human Resources function, including talent acquisition, learning and development and organizational development as well as be responsible for the company’s Diversity and Inclusion programs.

Dr. Pretorius joined PAREXEL in 1996 and previously held leadership roles in various countries. He serves as Chief Scientific Officer and works closely with clients to design and optimize drug and device development strategies as well as find, evaluate and purchase assets. He will continue to be responsible for the overall leadership of several service offerings, including PAREXEL’s global Early Phase business, Global Medical Services, Quantitative Clinical Development and Genomic Medicine.

Mr. Schultz joined PAREXEL in 2005 and oversees the global Late Phase business, which provides clinical research services in the peri/post-approval phases, including IIIb/IV clinical trials, observational research, market access, medical communications and patient safety services. He will continue to lead PAREXEL Access.